Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.150
-0.015 (-1.29%)
At close: May 15, 2026, 4:00 PM EDT
1.140
-0.010 (-0.87%)
After-hours: May 15, 2026, 4:54 PM EDT
Pliant Therapeutics Employees
Pliant Therapeutics had 49 employees as of December 31, 2025. The number of employees decreased by 122 or -71.35% compared to the previous year.
Employees
49
Change (1Y)
-122
Growth (1Y)
-71.35%
Revenue / Employee
n/a
Profits / Employee
-$2,310,571
Market Cap
71.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 49 | -122 | -71.35% |
| Dec 31, 2024 | 171 | 13 | 8.23% |
| Sep 30, 2024 | 166 | 7 | 4.40% |
| Jun 30, 2024 | 166 | 11 | 7.10% |
| Mar 31, 2024 | 158 | 22 | 16.18% |
| Dec 31, 2023 | 158 | 34 | 27.42% |
| Sep 30, 2023 | 159 | 45 | 39.47% |
| Jun 30, 2023 | 155 | 45 | 40.91% |
| Mar 31, 2023 | 136 | 35 | 34.65% |
| Dec 31, 2022 | 124 | 33 | 36.26% |
| Sep 30, 2022 | 114 | 24 | 26.67% |
| Jun 30, 2022 | 110 | 20 | 22.22% |
| Mar 31, 2022 | 101 | 11 | 12.22% |
| Dec 31, 2021 | 91 | 13 | 16.67% |
| Sep 30, 2021 | 90 | 20 | 28.57% |
| Jun 30, 2021 | 90 | 23 | 34.33% |
| Mar 31, 2021 | 90 | 28 | 45.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| XBiotech | 85 |
| Fortress Biotech | 78 |
| ImmuCell | 73 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Gain Therapeutics | 21 |
| Rallybio | 14 |
PLRX News
- 4 days ago - Pliant Therapeutics reports Q1 EPS (32c), consensus (36c) - TheFly
- 4 days ago - Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Pliant Therapeutics doses first participant in FORTIFY expansion trial - TheFly
- 15 days ago - Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - GlobeNewsWire
- 26 days ago - Pliant announces presentation of updated data from Phase 1 trial of PLN-101095 - TheFly
- 27 days ago - Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Pliant Therapeutics files $300M mixed securities shelf - TheFly